Loading blog post…
A complete guide to finasteride for androgenetic alopecia — 5-alpha reductase inhibition mechanism, Merck pivotal trials, sexual side effects and post-finasteride syndrome, dutasteride comparison, and who is a candidate.
· By MedSpot Editorial · 5 min read
Finasteride is the most evidence-backed oral treatment for male androgenetic alopecia (male pattern hair loss) — FDA-approved, supported by decades of controlled trials, and mechanistically precise. It also carries the most discussed side effect profile of any hair loss medication. Here's the complete, unbiased breakdown.
Finasteride is a synthetic 4-azasteroid — a competitive inhibitor of 5-alpha reductase (5AR) type II, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the scalp, prostate, and liver.
FDA approvals:
Off-label: Finasteride 1–2.5 mg is increasingly used off-label in women with androgenetic alopecia — discussed separately below.
In genetically susceptible scalp follicles, DHT (dihydrotestosterone) binds to androgen receptors in dermal papilla cells → triggers follicular miniaturization — a progressive process where each hair cycle produces a thinner, shorter hair, ultimately resulting in terminal-to-vellus hair transition (visible thinning).
DHT is 5× more potent than testosterone at androgen receptors in the scalp. The genetic susceptibility is in the follicular androgen receptor sensitivity, not in DHT levels themselves — which is why men with AGA often have normal serum DHT.
Finasteride competitively inhibits 5AR type II:
By reducing DHT, finasteride slows or halts follicular miniaturization — and in many patients allows partial reversal (miniaturized follicles produce thicker hair again).
Finasteride's approval rests on two large multicenter RCTs:
Kaufman et al. (1998, Journal of the American Academy of Dermatology) — 1,553 men aged 18–41 with mild-to-moderate AGA, randomized to finasteride 1 mg vs. placebo for 2 years:
Long-term (5 years, Kaufman et al. 1999): Efficacy maintained at 5 years with continued use; discontinuation results in return to pre-treatment hair loss trajectory within 6–12 months.
Finasteride is more effective for vertex (crown) hair loss than frontal hairline recession. The reasons are not fully characterized but likely relate to androgen receptor density differences between scalp regions. For advanced frontal recession, finasteride slows loss but produces less visible regrowth.
The most discussed concern — documented in clinical trials and subsequent population studies:
Trial-reported rates (finasteride 1 mg):
In the clinical trials, these resolved on discontinuation in the majority of affected patients.
A subset of patients report persistent sexual and cognitive side effects after discontinuing finasteride — including persistent erectile dysfunction, reduced libido, decreased penile sensitivity, brain fog, depression, and anxiety — that do not resolve with cessation.
The evidence status: PFS is contested in the medical literature:
Honest clinical position: PFS is a real reported phenomenon in a subset of patients. The incidence is unknown but likely below 5%. It cannot be predicted in advance. Patients should be fully informed before starting finasteride.
Dutasteride inhibits both 5AR type I and type II (vs. finasteride's type II only):
| Finasteride 1 mg | Dutasteride 0.5 mg | |
|---|---|---|
| 5AR inhibition | Type II only | Type I + II |
| Scalp DHT reduction | ~60–70% | ~90% |
| Serum DHT reduction | ~65% | ~90–95% |
| FDA approval for AGA | Yes (1 mg) | No (off-label for AGA) |
| FDA approval for BPH | Yes (5 mg) | Yes (0.5 mg) |
| Hair regrowth evidence | Very strong | Strong (slightly superior) |
| Side effect profile | Established | Similar; potentially higher at BPH doses |
| Half-life | 5–6 hours | ~5 weeks |
Clinical implication: Dutasteride produces greater DHT suppression and in head-to-head trials produces modestly greater hair regrowth than finasteride. However, its extremely long half-life (5 weeks) means side effects — if they occur — take much longer to resolve after discontinuation. The FDA has not approved dutasteride for AGA (though Korea has, and it is standard practice in Korean dermatology).
Finasteride is used off-label for female androgenetic alopecia at doses of 1–2.5 mg/day. Evidence base is smaller than the male AGA data:
Iorizzo et al. (2006) — a controlled study of finasteride 2.5 mg/day in postmenopausal women with AGA found significant improvement in hair density vs. placebo.
Premenopausal women: Must use reliable contraception — finasteride is absolutely contraindicated in pregnancy. Many prescribers require OCP co-prescription. The risk-benefit calculation is individualized.
The strongest medical protocol for male AGA combines finasteride + minoxidil (topical or low-dose oral):
Khandpur et al. (2020, JAMA Dermatology)** — RCT of finasteride vs. minoxidil vs. combination found the combination produced significantly greater hair density improvement than either monotherapy.
Mechanism rationale: Finasteride reduces the hormonal driver (DHT); minoxidil directly stimulates the follicle through KATP channels and VEGF — completely different pathways. Combination is additive.
Looking for a hair loss consultation? Browse hair restoration providers on MedSpot →